Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Patient Square Capital

            Deal Size: $145.0 million Upfront Cash: Undisclosed

            Deal Type: Financing June 17, 2021

            Details:

            Proceeds from the investment will support advancement of Apollo's robust pipeline into development, expansion of the company's operations including establishment of a presence in the Boston, MA area and pursuit of new collaborations globally.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $505.5 million Upfront Cash: $8.5 million

            Deal Type: Licensing Agreement April 12, 2021

            Details:

            C4XD’s small molecule IL-17A inhibitor programme can selectively block IL-17 activity in vivo while maintaining the molecular size of the molecule in the traditional “drug-like” range suitable for oral administration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SDC-1802

            Therapeutic Area: Immunology Product Name: SDC-1802

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2021

            Details:

            The United States Patent and Trademark Office has now formally approved its patent application (US Patent Application no. 16/351,620), in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 K